U.S. Court Action Could Jeopardize Ranbaxy-Daiichi Merger Plans
This article was originally published in PharmAsia News
Executive Summary
U.S. allegations Ranbaxy Laboratories may have adulterated some generic drugs marketed in the United States could trouble the proposed purchase of India's largest drug maker by Japan's Daiichi Sankyo. Drug industry analysts are concerned the nature of the accusations leveled in a motion in U.S. court by the Justice Department could derail the merger plan. Experts believe Ranbaxy already must have informed Daiichi about the investigation, which the Indian company has acknowledged publicly is taking place. A Daiichi spokesperson said the firm was studying legal liabilities involved. (Click here for more